Antecip Bioventures II LLC is a private company headquartered in New York, NY, that develops, manufactures and sells medical applications.

Nippon Zoki Pharmaceutical Co. Ltd. is a private company headquartered in Chuo-ku, Japan, that manufactures pharmaceutical products.

Cellix Bio Pvt Ltd. is a biopharmaceutical company, which engages in the development and discovery of novel drugs. It specializes in the treatment of neurology, dermatology, gastrointestinal, inflammation, metabolic and life style, oncology, ophthalmology, and infectious diseases. The company was founded by Mahesh Kandula on May 21, 2014 and is headquartered in Hyderabad, India.

Shenzhen Ruijian Biotechnology Co., Ltd., established on 2019-03-25, Business scope includes general business items:Health products,Technical consultation for medical devices,Technical Services,technology development,technology transfer;medical technology,chemical technology,Biotechnology research and development and consulting;Biological product(Does not contain drugs)technology development;Technology development of biotechnology products;New Energy Technology Development;Laboratory Instruments and Consumables,Detection Reagent,Sales of testing instruments and consumables;Chemical Products(Free of Hazardous Chemicals),Polymer Materials,R&D and sales of fiber materials, process technology and equipment(Free of Hazardous Chemicals);On-site maintenance and technical consultation of experimental equipment;Business Management Consulting;Invest in business(Specific projects will be reported separately);Domestic Trade(Does not contain franchise,monopoly,Specially Controlled Commodities);Operating import and export business(law,Administrative regulations,Except for items prohibited by the State Council,Restricted projects must obtain a license before operating).,The licensing program is:Sales of pharmaceuticals and medical devices.

Abiogen Pharma is a pharmaceutical company that conducts research and development, manufactures pharmaceuticals under its own brand or under third-party contracts, and markets its own and licensed drugs. Its therapeutic areas of interest include bone metabolism, pain management, respiratory, metabolic (diabetes), and dermatological disorders.

Curemark is a biopharmaceutical company that focuses on the development of novel therapies to treat serious diseases for which there are limited treatment options for patients in need. Their pipeline includes two Phase III clinical-stage programs for Autism and ADHD as well as three preclinical programs directed at Parkinson’s Disease, Schizophrenia, and Addiction. All of their product candidates address severe neurologic diseases that are currently believed to be underserved by available approved therapies and represent large potential commercial market opportunities. They believe that their product candidates offer innovative therapeutic approaches and may have the potential to provide significant advantages relative to current therapies.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, has received approval of their Investigational New Drug (IND) application for CT-044 from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed (commence phase I dosing June 2019). CT-044, a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy.

Axsome Therapeutics is a biopharmaceutical company developing novel therapies for the treatment of pain and other neurological diseases. By focusing on this therapeutic area, Axsome is addressing growing markets where current treatment options are limited or inadequate. Axsome has a balanced portfolio of clinical development stage as well as research stage products. Axsome Therapeutics aims to become a fully integrated biopharmaceutical company that develops and commercializes differentiated products which increase the armamentarium of caregivers and improve the lives of patients. While the focus of the company is on developing its internally derived product candidates, Axsome also evaluates potential in-licensing opportunities to supplement its current portfolio.

The United States Department of Veterans Affairs (VA) is a federal Cabinet-level agency that provides near-comprehensive healthcare services to eligible military veterans at VA medical centers and outpatient clinics located throughout the country; several non-healthcare benefits including disability compensation, vocational rehabilitation, education assistance, home loans, and life insurance; and provides burial and memorial benefits to eligible veterans and family members at 135 national cemeteries.

An internationally-recognized model of excellence in biomedical research and known for its multidisciplinary training centre, the IRCM brings together 33 research units grouped together into five research divisions and houses four specialized clinics as well as a research centre of rare and genetic diseases in adults. Equipped with state-of-the-art technology, our research teams are dedicated to basic and clinical research and contribute significantly to scientific progress. The IRCM is affiliated with the Université de Montréal and associated with McGill University.see less

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

BMI Korea Co., Ltd. is a South Korean private company. The firm manufactures drugs and medicines.

XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in the United States by XenoPort. Regnite® (gabapentin enacarbil) Extended-Release Tablets is approved and being marketed in Japan by Astellas Pharma Inc. XenoPort holds all other world-wide rights to gabapentin enacarbil. XenoPort's pipeline of product candidates includes potential treatments for patients with Parkinson's disease, relapsing-remitting multiple sclerosis and psoriasis.

ZARS Pharma, Inc. develops and distributes drugs. It is a specialty pharmaceutical company focused on the development and commercialization of topically administered drugs, primarily for the treatment of pain, using its proprietary drug delivery technologies. The company was founded by Jie Zhang, Theodore H. Stanley, Larry D. Rigby and Michael A. Ashburn in 1996 and is headquartered in Salt Lake City, UT.